DuoTrav a success

The introduction of DuoTrav (travoprost 0.004%/timolol 0.5%) offers a greater probability of success in reaching target intraocular pressure (IOP) with a single drop, according to Dr Raber, an Alcon consultant from Freiburg, Germany.

Dr Raber conducted a non-observational, open-label, multicentre, six-week trial of 7,000 subjects with primary open angle glaucoma (POAG) and ocular hypertension (OHT). The aim was to test the safety and efficacy of DuoTrav. Tolerability was evaluated in five steps ranging from "unsatisfactory" to "excellent" by the patient. IOP was recorded at baseline and after four to six weeks of therapy.

Analysis of the results revealed significant reductions in IOP when switching from latanoprost or latanoprost/timolol fixed combinations to DuoTrav.